Last reviewed · How we verify
Shigella flexneri 2a Invaplex 50 — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Shigella flexneri 2a Invaplex 50 (Shigella flexneri 2a Invaplex 50) — U.S. Army Medical Research and Development Command.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Shigella flexneri 2a Invaplex 50 TARGET | Shigella flexneri 2a Invaplex 50 | U.S. Army Medical Research and Development Command | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Shigella flexneri 2a Invaplex 50 CI watch — RSS
- Shigella flexneri 2a Invaplex 50 CI watch — Atom
- Shigella flexneri 2a Invaplex 50 CI watch — JSON
- Shigella flexneri 2a Invaplex 50 alone — RSS
Cite this brief
Drug Landscape (2026). Shigella flexneri 2a Invaplex 50 — Competitive Intelligence Brief. https://druglandscape.com/ci/shigella-flexneri-2a-invaplex-50. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab